Novo CSO: New obesity treatment might prove as effective as surgery
Danish Novo Nordisk's new obesity candidate brings the company one step closer to the dream of developing a medical treatment that is as effective as surgery, says CSO Mads Krogsgaard Thomsen.
When Novo Nordisk presented its quarterly results last month, the Danish drug group also announced the initiation of phase II with the candidate AM833.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo and Lundbeck have reduced R&D intensity
For abonnenter
